强胰降糖胶囊对四氧嘧啶小鼠和家兔血糖的影响

研究纯中药制剂强胰降糖胶囊治疗糖尿病的药理作用，结果表明，强胰降糖胶囊能降低四氧嘧啶糖尿病小鼠，家兔的血糖，降低四氧嘧啶糖尿病小鼠的24h饮水量、进食量，对体重无影响。     

RP-HPLC测定犬血浆中卡托普利

目的　采用反相高效液相色谱法测定犬血浆中卡托普利浓度。方法　以对溴苯乙酰基溴为衍生剂 ,血浆样品经衍生反应后 ,用乙酸乙酯 -苯 (1∶1)提取 ,以ODSC18为固定相 ,乙腈∶水∶冰醋酸 (4 5∶5 5∶0 2 )为流动相 ,UV2 5 8nm紫外检测。结果　在 2 5～ 6 0 0 μg·L-1浓度范围线性良好 ,最小检测浓度为 12 5 μg·L-1。其日内差及日间差RSD分别小于 4 95 %和 2 88% ,相对回收率大于 94 8%。结论　方法简便灵敏 ,为卡托普利样品分析及临床药物监测提供了检测方法。     

多肽药物分析方法研究进展

介绍多肽药物的生物活性分析、结构分析、纯度分析的发展状况。     

93例扁桃体鳞癌的治疗分析

目的 探讨扁桃体鳞癌治疗方式。方法 本院自1987年到1996年共收治扁桃体鳞癌93例，回顾性分析其临床资料。结果 扁桃体鳞癌预后与病理分级、临床分期、治疗方法等诸多因素相关。本院采用根治手术 术后放疗的综合疗法治疗中晚期扁桃体鳞癌22例，5年生存率达68．18％。结论 治疗除早期病例可考虑行单纯手术或单纯放疗外，中晚期病例应采取以手术为主的综合治疗。     

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.

PURPOSE: To determine the response rate, time to disease progression, survival duration and rate, and toxicity with the combination of cetuximab and gemcitabine in patients with epidermal growth factor receptor (EGFR)-expressing advanced pancreatic cancer. PATIENTS AND METHODS: Patients with measurable locally advanced or metastatic pancreatic cancer who had never received chemotherapy for their advanced disease and had immunohistochemical evidence of EGFR expression were eligible for the multicenter phase II trial. Patients were treated with cetuximab at an initial dose of 400 mg/m(2), followed by 250 mg/m(2) weekly for 7 weeks. Gemcitabine was administered at 1,000 mg/m(2) for 7 weeks, followed by 1 week of rest. In subsequent cycles, cetuximab was administered weekly, and gemcitabine was administered weekly for 3 weeks every 4 weeks. RESULTS: Sixty-one patients were screened for EGFR expression, 58 patients (95%) had at least 1+ staining, and 41 were enrolled onto the trial. Five patients (12.2%) achieved a partial response, and 26 (63.4%) had stable disease. The median time to disease progression was 3.8 months, and the median overall survival duration was 7.1 months. One-year progression-free survival and overall survival rates were 12% and 31.7%, respectively. The most frequently reported grade 3 or 4 adverse events were neutropenia (39.0%), asthenia (22.0%), abdominal pain (22.0%), and thrombocytopenia (17.1%). CONCLUSION: Cetuximab in combination with gemcitabine showed promising activity against advanced pancreatic cancer. Further clinical investigation is warranted.     

Treatment of 78 cases of shoulder periarthritis by warming-needle method

Jiansanzhen, Tianzong (SI 11), Jugu (LI 16), Jianzhen (SI 9), Binao (LI 14) and Quchi (LI 11) were given warming-needle moxibustion to treat shoulder periarthritis in 78 cases, and the result showed total effective rate was 97.4%. Author: LI Jian-wu (1955-), male, junior consultant doctor Translator: WU Xue-fei     

Marimastat对裸鼠原位种植人胃癌生长和转移抑制的实验研究

目的 探讨基质金属蛋白酶抑制剂Marimastat对胃癌生长和转移的抑制作用。方法 采用人胃腺癌细胞株SGC—7901完整组织块棵鼠原位种植，建立胃癌转移模型。移植7天后开始腹腔内注射Marimastat，隔天1次，剂量为0mg/kg(对照组)、10mg/kg、30mg/kg、60mg/kg(治疗组)，共用8周，第9周处死动物，测量原位肿瘤大小、抑瘤率、肿瘤微血管密度(MVD)、MMP—9的高表达率、观察肿瘤转移情况。结果 治疗组原位肿瘤瘤重明显较对照组轻，肿瘤肝脏转移、腹膜转移、肿瘤组织微血管密度和肿瘤组织MMP—9高表达率与对照组比较，均有显著性差异(P＜0．05)，且与Marimastat剂量呈正相关。结论 Marimastat对体内胃癌的生长及转移均有抑制作用。     

大鼠慢性肾功能不全模型的建立

目的 研制一种特殊的大鼠慢性肾功能不全模型。方法 手术摘除右肾后１周,重复２次静注阿霉素,观察２～１２周时大鼠２４ｈ尿蛋白排泄量和３个月时的肾功能、病理组织学改变。结果 模型组大鼠除呈明显肾病综合征表现外,血尿素氮和肌酐水平较正常组明显增加,尿渗透压降低;病理学检查显示该组大鼠硬化肾小球增多,站球硬化指数增加,小管间质炎症细胞浸润,灶性站管萎缩。结论 右肾摘除和阿霉素注射均可导致肾损害,两者联合应     

经去颧弓扩大颞下入路切除海绵窦,岩尖,上斜坡肿瘤

本文介绍采用改进的去颧弓扩大颞下入路手术治疗８例位于或累及海绵窦、岩骨尖部、上斜坡、天幕游离前外缘肿瘤患者。该方法的要点是断去颧弓，扇形形成颞肌瓣，翻向颧弓断段以下，咬除蝶骨嵴外侧部分，形成低位颞额骨窗，仅轻度上抬颞叶，则可充分暴露病变范围。由于手术空间扩大，更利于肿瘤切除。本组８例均达到全部或大部分切除，患者术后均得以康复，原有体征不同程度改善。     

复方蚁酒的抗炎补肾阳作用研究

复方蚁酒能明显抑制二甲苯、琼脂引起的小鼠耳、足肿胀、抑制蛋清引起的大鼠足肿胀和佐剂性关节炎，并能对抗氢化考的松引起的肾阳虚症，同时还具有增强免疫功能的作用。